Literature DB >> 16650445

Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers.

Guillermo Lamolle1, Mónica Marin, Fernando Alvarez-Valin.   

Abstract

The last release of p53 somatic mutation database contains more than 20,000 of mutation among which 951 are silent (synonymous). This striking amount of silent mutations is much more than what would be expected if synonymous mutations were effectively neutral. The prevalent explanation to reconcile this vast amount of silent mutations with the neutral expectation is that they are just the subproduct of the hypermutability process that affect cancer cells. Some evidences have been presented in this direction, and the explanation has been taken as granted. Assuming that silent mutations are effectively neutral has major implication in the investigation of mutational processes that affect the gene encoding the p53 protein, since on the basis of this assumption they are considered the Null hypothesis, for instance for measuring and comparing among tissues the endogenous mutability. From this it follows that determining whether silent mutations in the p53 gene, and in all disease genes in general, are or not basically mutational noise, is of paramount importance. In this paper we readdress this topic by testing whether there is a relationship between the spatial distribution of silent mutations inside the p53 gene and functional significant features of the gene. For this purpose we divided the population of silent mutations in three groups: those that are found accompanied by other mutations (doublets and multiplest), those that were isolated as singlets, but the same mutation was also isolated as being part of a doublet (or multiplet) in another individual. And the last group is composed by those that were always found as singlets and never as being part of a doublet or a multiplet. This last group was expected to be enriched in functionally significant silent mutations. We found that all silent mutations, but particularly those of the last group, are preferentially located in conserved amino acid positions (i.e. functionally important amino acids) and also tend to be located inside suspected splicing enhancers. Noteworthy, this association remains even after eliminating the possible contribution of mutation hotspots. Besides, we present additional evidence in the direction that these putative splicing enhancers are real functional enhancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650445     DOI: 10.1016/j.mrfmmm.2006.03.004

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  11 in total

Review 1.  Whisper mutations: cryptic messages within the genetic code.

Authors:  R Fåhraeus; M Marin; V Olivares-Illana
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

Review 2.  Protein folding and tRNA biology.

Authors:  Mónica Marín; Tamara Fernández-Calero; Ricardo Ehrlich
Journal:  Biophys Rev       Date:  2017-09-24

Review 3.  Clinical Outcomes of TP53 Mutations in Cancers.

Authors:  Ana I Robles; Jin Jen; Curtis C Harris
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

4.  Synonymous polymorphisms at splicing regulatory sites are associated with CpGs in neurodegenerative disease-related genes.

Authors:  Maria Karambataki; Andigoni Malousi; Nicos Maglaveras; Sofia Kouidou
Journal:  Neuromolecular Med       Date:  2010-01-14       Impact factor: 3.843

5.  A Massively Parallel Fluorescence Assay to Characterize the Effects of Synonymous Mutations on TP53 Expression.

Authors:  Geetha Bhagavatula; Matthew S Rich; David L Young; Maximillian Marin; Stanley Fields
Journal:  Mol Cancer Res       Date:  2017-06-26       Impact factor: 5.852

6.  Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.

Authors:  Carolina Cavaliéri Gomes; Marina Gonçalves Diniz; Lissur Azevedo Orsine; Alessandra Pires Duarte; Thiago Fonseca-Silva; Brendan I Conn; Luiz De Marco; Cláudia Maria Pereira; Ricardo Santiago Gomez
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

7.  p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.

Authors:  Cigdem Ercan; Paul J van Diest; Bram van der Ende; John Hinrichs; Peter Bult; Horst Buerger; Elsken van der Wall; Patrick W B Derksen
Journal:  Cell Oncol (Dordr)       Date:  2012-02-22       Impact factor: 6.730

8.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

9.  Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.

Authors:  Jitra Kriangkum; Amanda Warkentin; Amanda Warkinton; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

Review 10.  Alternative splicing for diseases, cancers, drugs, and databases.

Authors:  Jen-Yang Tang; Jin-Ching Lee; Ming-Feng Hou; Chun-Lin Wang; Chien-Chi Chen; Hurng-Wern Huang; Hsueh-Wei Chang
Journal:  ScientificWorldJournal       Date:  2013-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.